Updated practice guidelines and recently approved novel therapies provide improved strategies to optimize care for patients with heart failure (HF), particularly heart failure with reduced ejection fraction (HFrEF). Among these advances are tools and biomarkers for risk stratification, the use of sodium glucose-cotransporter-2 (SGLT2) inhibitors for appropriate patients with or without type 2 diabetes, and the role of a new soluble guanylate cyclase (sGC) inhibitor to reduce the risk of cardiovascular death and HF hospitalizations in worsening disease.
The key to improving patient care is regular clinical implementation of the new recommendations. This CMEOCast episode features two experts in HF assessing a patient who presents with worsening HFrEF, discussing additional workups that would be helpful, optimizing his current medication regimen, and sequencing newer therapies. Faculty will also discuss strategies on how to utilize shared decision-making and avoid racial and ethnic bias to ensure all patients receive appropriate, guideline-directed medical therapy.
At the end of this CME/CE activity, participants should be able to:
Supported by an educational grant from Merck Sharp & Dohme Corp.
Cardiologists, PCPs, PAs, NPs, Nurses, Pharmacists
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Butler reports that he is on the speakers bureau for AstraZeneca; Boehringer Ingelheim (BI)-Lilly Alliance; Janssen Pharmaceuticals, Inc.; and Novartis Pharmaceuticals Corporation. He is a consultant for Abbott; Adrenomed; Amgen Inc.; Applied Therapeutics; Array BioPharma Inc.; AstraZeneca; Bayer; Boehringer Ingelheim; CVRx; G3 Pharmaceuticals; Impulse Dynamics; Innolife Pharma, Inc.; Janssen Pharmaceuticals, Inc; LivaNova; Luitpold Pharmaceuticals, Inc.; Medtronic; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Relypsa, Inc.; Sequanna Medical; and Vifor Pharma, Inc.
Dr. Morris reports that she receives research support from the Association of Black Cardiologists; National Institutes of Health/National Heart Lung, and Blood Institute; and the Robert W. Woodruff Foundation, Inc. She also reports Institutional Research Support (paid to Emory University): Alnylam Pharmaceuticals; Amgen Inc.; Boston Scientific Corporation; Eidos Therapeutics; Ionis; Merck & Co., Inc.; MyoKardia, Inc.; National Heart, Lung, and Blood Institute (NHLBI); and Pfizer Inc. She is a shareholder with direct purchase with Gilead Sciences, Inc.
Disclosures were obtained from the CME Outfitters, LLC staff; no disclosures to report:
CME Outfitters, LLC and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Call us at 877.CME.PROS (877.263.7767).